Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susaniba Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Castaneda Puglianini O, Rossi A, Lin Y, Atrash S, Sborov D, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD Jr, Lee HC, Anwer F, Ferreri CJ, Shune L. Dima D, et al. Among authors: sannareddy a. Blood Cancer J. 2025 Jun 25;15(1):111. doi: 10.1038/s41408-025-01314-9. Blood Cancer J. 2025. PMID: 40562770 Free PMC article.
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD Jr, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Pasvolsky O, et al. Among authors: sannareddy a. Blood Cancer J. 2025 May 9;15(1):92. doi: 10.1038/s41408-025-01297-7. Blood Cancer J. 2025. PMID: 40346049 Free PMC article.
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment.
Dima D, Afrough A, Goel U, Grajales-Cruz A, Khouri J, Julian K, Pasvolsky O, Banerjee R, Razzo B, Ferreri CJ, Vazquez Martinez MA, Davis JA, Sannareddy A, Castaneda Puglianini O, Raza S, Portuguese AJ, Gaballa MR, Rana M, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi AC, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall A, Lee HC, Anderson LD Jr, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Hansen DK, Atrash S, Susanibar-Adaniya SP. Dima D, et al. Among authors: sannareddy a. Blood Adv. 2025 Apr 8:bloodadvances.2025016059. doi: 10.1182/bloodadvances.2025016059. Online ahead of print. Blood Adv. 2025. PMID: 40198766
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Lin CH, Tariq MJ, Ullah F, Sannareddy A, Khalid F, Abbas H, Bader A, Samaras C, Valent J, Khouri J, Anwer F, Raza S, Dima D. Lin CH, et al. Among authors: sannareddy a. Int J Mol Sci. 2024 Jun 4;25(11):6192. doi: 10.3390/ijms25116192. Int J Mol Sci. 2024. PMID: 38892379 Free PMC article. Review.
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
Dima D, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, Mazzoni S, Mehdi A, Rudoni J, Raza S, De Simone N, Williams L, Khan A, Rashid A, Rice M, Ricci K, Samaras C, Valent J, Anderson LD Jr, Anwer F, Kaur G, Khouri J. Dima D, et al. Among authors: sannareddy a. Hematol Oncol. 2024 Jul;42(4):e3293. doi: 10.1002/hon.3293. Hematol Oncol. 2024. PMID: 38872511
Toxicity of CAR T-Cell Therapy for Multiple Myeloma.
Afrough A, Abraham PR, Turer L, Kaur G, Sannareddy A, Hansen DK, Anderson LD Jr. Afrough A, et al. Among authors: sannareddy a. Acta Haematol. 2025;148(3):300-314. doi: 10.1159/000539134. Epub 2024 May 8. Acta Haematol. 2025. PMID: 38718775 Free PMC article. Review.
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Afrough A, et al. Among authors: sannareddy a. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. Blood Cancer J. 2024. PMID: 38609386 Free PMC article. No abstract available.
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H. Dima D, et al. Among authors: sannareddy a. Transplant Cell Ther. 2024 Mar;30(3):308.e1-308.e13. doi: 10.1016/j.jtct.2023.12.016. Epub 2023 Dec 26. Transplant Cell Ther. 2024. PMID: 38151105 Free article.